Moderna/Merck—first out of the gate with a personal neoantigen cancer vaccine—who else is in the race and what strategy(ies) will win?

Immuno-Oncology and Technology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles